CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research
LEHI, Utah, March 24, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies discussed the future of the cancer therapeutic industry with Dr. Looper, a life-long researcher in the chemistry field.
Ryan Looper, Ph.D., Colorado State University, is a tenured Professor at the University of Utah. Dr. Looper started with his B.S. in Chemistry from Western Washington University before beginning his Ph.D. in Organic Chemistry. To top off his academic credentials, Dr. Looper was a post-doctorate fellow at Harvard University, where he studied Chemical Biology. Before beginning his current role as a Professor at the University of Utah, Dr. Looper was the John Huntsman Presidential Chair with the Huntsman Cancer Institute. Dr. Looper’s work as a researcher sits at the corner of a passion for helping young academics find their future career and the forefront of new therapeutics. He noted a need for helping young scientists find a path they’re passionate about.
Dr. Looper enthusiastically discussed a natural product he’s attempting to replicate from the Panamanian Golden Frog. “This molecule is so complex, I would imagine by now there are 25 to 30 chemist years that have been put towards synthesizing this molecule, and we still don't have it replicated in hand,” Dr. Looper said. He continued that such a project would be ideal for a passionate young graduate student to work on.
“Speaking with Dr. Looper was an exciting opportunity to see how industry researchers are encourging young scientists to work towards their goals in therapeutic development,” CancerVAX CEO Ryan Davies said. “Dr. Looper and his colleagues are truly one of the greatest driving forces forward for a solution to many of our therapeutic challenges.”
This CEO Chat can be viewed at https://youtu.be/uDGsblCmks4
For more information about CancerVax, please visit http://www.cancervax.com/.
CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with an incredibly high level of precision. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s own immune system to destroy cancer cells. As we develop our universal cancer vaccine, we are also working with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot.
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.